期刊文献+

加替沙星无菌检查方法的建立与标准操作探讨 被引量:19

Establish and standard operation process(SOP)discuss in sterility test for gatifloxacin
下载PDF
导出
摘要 目的:建立加替沙星原料及制剂无菌检查法及标准操作方法。方法:按2005年版中国药典无菌检查法验证实验的有关要求,通过接种阳性代表菌株,对薄膜过滤、添加中和剂等去除加替沙星抗菌活性的实验方法和条件进行验证,逐步建立加替沙星原料及制剂无菌检查的标准操作方法。结果:在对加替沙星不同原料及制剂样品适当的处理基础上,采用薄膜过滤法,以0.1%蛋白胨水溶液作为冲洗液,约每滤筒300 mL 的冲洗量,每筒培养基中加入0.1 mol·L^(-1)硫酸锰溶液3 mL 可去除加替沙星对细菌的抑菌作用。结论:加替沙星具有较强的抑菌活性,通过适当的样品处理、薄膜过滤法和添加硫酸锰溶液作为重金属络合剂,去除加替沙星抑菌活性,可对解决喹诺酮类抗生素无菌检查问题起到较好的参考作用。 Objective:To establish the standard operation process (SOP)in sterility test for gatifloxacin raw material and preparation. Methods:According to the Chinese pharmacopoeia (2005 edition), validate the sterility test method of gatifloxacin sample that treated with membrane -filter procedure and neutralizer by control bacteria, which testify the antimicrobial activity was removed thoroughily or not. Results:when the filter was washed with 0. 1% peptone solution 300 mL and 0. 1 mol · L^-1 manganese sulfate solution 3 mL was added into per culture vessel,the control bacteria that added into the culture vessel treated gatifloxacin sample grewth commonly as the positive control. Conclution: The antimicrobial activity strongly of gatifloxacin is able to remove through membrane - filter procedure and neutralizer of metal chelating agent as manganese sulfate. This method is not only an effective SOP in sterility test for gatifloxacin but a valuable reference for other quinolone.
出处 《药物分析杂志》 CAS CSCD 北大核心 2007年第6期877-880,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 加替沙星 无菌检查 中和剂 硫酸锰 gatifloxacin sterility test neutralizer manganese sulfate
  • 相关文献

参考文献10

二级参考文献41

  • 1裴保香,郭绍来,王睿,周筱青.大肠埃希菌耐药性与头孢菌素类用量变化的相关性分析[J].中华医院感染学杂志,2004,14(4):373-376. 被引量:35
  • 2许宏涛,陈东科,俞云松,张秀珍.多重耐药铜绿假单胞菌产β-内酰胺酶耐药机制研究[J].中华医院感染学杂志,2005,15(1):20-22. 被引量:81
  • 3赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 4[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108~2117.
  • 5[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594~601.
  • 6[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447~452.
  • 7[4]National Committee for Clinical Laboratory Standards. 1998;18.
  • 8[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293~301.
  • 9[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215~2219.
  • 10[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239~244.

共引文献133

同被引文献166

引证文献19

二级引证文献219

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部